Search research articles
Contact Us
Filters
Showing results (591-600 of 762) with videos related to
Page
of 77
Sort By:
Urology
|
September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?
Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Journal of Medicinal Chemistry
|
January 1, 1978
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate
C J Barnett, G J Cullinan, K Gerzon, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 30, 2014
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation
Chen-Lin Hsieh, Teng Fei, Yiwen Chen, et al.
Cancer Discovery
|
December 8, 2021
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Claire F Friedman, John D Hainsworth, Razelle Kurzrock, et al.
The Breast Journal
|
March 12, 2021
Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre
Matthew G Davey, Éanna J Ryan, Sami Abd Elwahab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2015
Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer
Donghao Lu, Jennifer A Sinnott, Unnur Valdimarsdóttir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
David B Agus, Christopher J Sweeney, Michael J Morris, et al.
European Urology
|
April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 5, 2015
Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients
Vinayak Muralidhar, Ming-Hui Chen, Gally Reznor, et al.
Page
of 77
Search research articles
Search
Showing results (591-600 of 762) with videos related to
Sort By:
Page
of 77
Urology
|
September 23, 2015
Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?
Kathryn T Dinh, Vinayak Muralidhar, Brandon A Mahal, et al.
Journal of Medicinal Chemistry
|
January 1, 1978
Structure-activity relationships of dimeric Catharanthus alkaloids. 1. Deacetylvinblastine amide (vindesine) sulfate
C J Barnett, G J Cullinan, K Gerzon, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 30, 2014
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation
Chen-Lin Hsieh, Teng Fei, Yiwen Chen, et al.
Cancer Discovery
|
December 8, 2021
Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Claire F Friedman, John D Hainsworth, Razelle Kurzrock, et al.
The Breast Journal
|
March 12, 2021
Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre
Matthew G Davey, Éanna J Ryan, Sami Abd Elwahab, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2018
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K Morgans, Yu-Hui Chen, Christopher J Sweeney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 23, 2015
Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer
Donghao Lu, Jennifer A Sinnott, Unnur Valdimarsdóttir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 20, 2007
Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy
David B Agus, Christopher J Sweeney, Michael J Morris, et al.
European Urology
|
April 22, 2023
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues
Nick Beije, Wassim Abida, Emmanuel S Antonarakis, et al.
International Journal of Radiation Oncology, Biology, Physics
|
November 5, 2015
Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients
Vinayak Muralidhar, Ming-Hui Chen, Gally Reznor, et al.
Page
of 77